Janux Therapeutics Current Deferred Revenue (Quarterly) Analysis

Janux Therapeutics, Inc. (JANX)

13.83 -0.24 (-1.71%) USD | NASDAQ | Dec 30, 15:15

View Current Deferred Revenue (Quarterly) for JANX.
Upgrade now.

Sep '18

Jan '19

May '19

285.00

270.00

255.00

240.00

View Current Deferred Revenue (Quarterly) Chart

Start Trial

View Historical Data

Start Trial

View Current Deferred Revenue (Quarterly) Range, Past 5 Years

Start Trial

Minimum

Maximum

Average

Median

View Current Deferred Revenue (Quarterly) Benchmarks

Start Trial

Eli Lilly & Co.	--
Stoke Therapeutics, Inc.	Upgrade
Ionis Pharmaceuticals, Inc.	Upgrade
MannKind Corp.	Upgrade
Madrigal Pharmaceuticals, Inc.	--